Clinical trials
This page is designed to help you find clinical trials that may suit your needs. We hope that this additional information will make it easier to discover and access trials relevant to your medical condition.
Clinical trials can provide access to innovative treatments and serve as alternatives when standard options are not suitable. By offering a centralised resource, CLL Advocates aims to streamline the search process for patients, making trial opportunities more accessible and user-friendly.
To find a clinical trial that may be suitable for you, you can refer to the spreadsheet of available trials and follow these steps:
- Click here to review the Spreadsheet: Start by reviewing the clinical trials listed in the spreadsheet, focusing on details such as the trial’s purpose, location, and treatment options.
- Check Eligibility Criteria: Each clinical trial will have specific eligibility requirements, such as the type and stage of cancer, age, previous treatments, and overall health status.
- Consult with your doctor: You should discuss your interest in the clinical trial with your doctor or specialist. The healthcare provider can assess whether you would make a suitable candidate for available trials.
- Location and Accessibility: Check the trial locations and consider your ability to travel for participation. Some trials may require frequent visits, so geographic proximity and your mobility are important factors.
- Discuss Risks and Benefits: With the healthcare team, weigh the potential benefits of the trial treatments against the risks and side effects. This will help determine whether a particular trial is suitable for your health status and treatment goals.
- Reach Out for Further Information: Once a potential match is found, the patient or healthcare provider can contact the trial coordinator for additional information, such as how the trial will be conducted, timelines, and potential outcomes.
The potential benefits:
Access to New Treatments: Clinical trials often provide access to experimental treatments that are not yet available through standard healthcare. For CLL patients, these treatments may include the latest targeted therapies, immunotherapies, or drug combinations. By the time drugs are being tested in Phase 3 randomised trials they have already been tested extensively in Phase 1 and 2 studies looking at safety and efficacy.
Potential for Better Outcomes: New therapies in trials are designed to improve treatment effectiveness, reduce side effects, or offer solutions when standard treatments no longer work.
Contributing to Research: By participating, patients contribute to the development of future treatments, helping improve care for others with CLL.
Safety and Ethical Standards: Clinical trials in New Zealand, as in other countries, are conducted under strict regulatory and ethical standards, ensuring that patient safety is a top priority.
Enhanced Care: Patients in trials often receive more frequent monitoring and care as part of the study, which can improve their overall treatment experience. There is evidence that taking part in a clinical trial improves outcomes even in those people who do not receive the new drug.
CLINICAL TRIALS
CLINICAL TRIALS
Trail: BELLWAVE 011 – NCT06136559
- Outline of Trial: Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib)
- Patient Criteria: People with chronic CLL/SLL who have not received any prior therapy and treatment is required
- NZ Locations: North Shore, Middlemore, Waikato
- Status: Open
- Summary: A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants with Untreated CLL/SLL
- Link to Details: BELLWAVE
Trial: RATIONALISE – ACTRN12622000359730
- Outline of Trial: To find out if oral antibiotics can be used instead of immunoglobulin (Ig) for preventing infections
- Patient Criteria: Patients having an acquired hypogammaglobulinaemia secondary to a haematological malignancy, and have received Ig treatment for over 6 months
- NZ Locations: Wellington
- Status: Open
- Summary: A randomised controlled trial of continuing immunoglobulin therapy, or stopping with or without prophylactic antibiotics, on infection rate in patients
- Link to Details: RATIONALISE
Trial: LOXO-BTK-20030 – NCT05254743
- Outline of Trial: To compare the efficacy and safety of Pirtobritinib (LOXO-305) to ibrutinib in participants with CLL/SLL
- Patient Criteria: Confirmed diagnosis of CLL/SLL requiring therapy per CLL 2018 criteria
- NZ Locations: Dunedin, Waikato
- Status: Open
- Summary: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With CLL/SLL (BRUIN-CLL-314)
- Link to Details: LOXO-BTK-20030
Trial: BGB-16673-302 – NCT06846671
- Outline of Trial: To investigate use of BGB-16673 compared with investigator’s choice (idelalisib + rituximab or bendamustine + rituximab or venetoclax + rituximab retreatment)
- Patient Criteria: Confirmed diagnosis of CLL/SLL requiring therapy per CLL 2018 criteria AND previously received treatment for CLL with a BTKi AND BCL2i
- NZ Locations: North Shore Hospital
- Status: Open / Pending in NZ ??
- Summary: A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice in patients with CLL previously exposed to both BTK and BCL2 Inhibitors
- Link to Details: BGB-16673-302
Trial: BGB-21447-101 – NCT05828589
- Outline of Trial: Determine dosages for Bcl-2 Inhibitor BGB-21447
- Patient Criteria: Relapsed/Refractory of CLL/SLL
- NZ Locations: Auckland Hospital
- Status: Pending in NZ
- Summary: A Phase 1/1b Open-Label Dose-Escalation Study of Bcl-2 Inhibitor BGB-21447 in Patients with Mature B-Cell Malignancies
- Link to Details: BGB-21447-101
Trial: BGB-21447-101 – NCT05828589
- Outline of Trial: Determine dosages for Bcl-2 Inhibitor BGB-21447
- Patient Criteria: Relapsed/Refractory of CLL/SLL
- NZ Locations: Auckland Hospital
- Status: Pending in NZ
- Summary: A Phase 1/1b Open-Label Dose-Escalation Study of Bcl-2 Inhibitor BGB-21447 in Patients with Mature B-Cell Malignancies
- Link to Details: BGB-21447-101
Trial: BGB-11417-301 – NCT06073821
- Outline of Trial: Compare the duration patients live without CLL getting worse between participants who received venetoclax + obinutuzumab vs Sonrotoclax + Zanubrutinib
- Patient Criteria: Treatment naïve & needing treatment
- NZ Locations: Wellington, Christchurch, Tauranga, North Shore, Auckland
- Status: Active, not recruiting
- Summary: A Phase 3, Open-Label, Randomized Study of Sonrotoclax + Zanubrutinib compared With Venetoclax + Obinutuzumab in Patients with Previously untreated CLL
- Link to Details: BGB-11417-301
Trial: BGB-11417-101- NCT04277637
- Outline of Trial: Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
- Patient Criteria: Relapse/refractory had at least 2 prior therapies
- NZ Locations: Wellington, North Shore, Auckland
- Status: Active, not recruiting
- Summary: A Phase 3, Open-Label, Randomized Study of Sonrotoclax + Zanubrutinib compared With Venetoclax + Obinutuzumab in Patients with Previously untreated CLL
- Link to Details: BGB-11417-101
Trial: AbbVie M14-728 – NCT02966756
- Outline of Trial: A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects with Relapsed or Refractory CLL/SLL
- Patient Criteria: Relapsed/refractory CLL/SLL with 17p deletion
- NZ Locations: Christchurch
- Status: Active, not recruiting
- Summary: Phase 2, open-label, study, either in presence of 17p deletion or have failed a B-receptor BCRI therapy and also failed, or were unable to receive CIT irrespective of 17p status
- Link to Details: M14-728
The ClinTrial Refer has bridged a critical gap in clinical research, facilitating better knowledge management, and allowing more equitable access to clinical trials.
ClinTrial Refer supplies a current list of active and pending haematology clinical research trials in New Zealand updated monthly.
Designed for haematologists, research unit staff, general practitioners and patients. ClinTrial Refer has searchable clinical research trial details, hospital locations and contacts, and inclusion and exclusion criteria.
Use it to refer to trial sites and broaden patient access to clinical research studies. Filter by disease, hospital location, trial status and sponsor. Trial details allow the user to email or call participating trial units for further information and to refer a patient.
ClinTrial Refer is a project supported by the New Zealand Branch of HSANZ.
